Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo- and fluoxetine-controlled phase 3 study of vortioxetine in children aged 7 to 11 years with major depressive disorder
MOH_2018-01-28_000774Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (4 arms), sponsored by Lundbeck. Started Jan 2018; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on MOH_2018-01-28_000774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-01-28_000774.